Treace Medical Concepts, Inc. (TMCI) is a commercial-stage orthopedic medical device company best known for its Lapiplasty system for bunion correction. Because it is a stock, the central target is built from individual analyst price targets rather than any single published figure.
Three current, individually verified analyst price targets form the basis of this analysis: Truist's Richard Newitter set a Hold with a $5.00 target, Stifel's Rick Wise raised the stock to Buy with a $6.50 target (up from $4.50) in early November 2026, and Lake Street's Ben Haynor reiterated a Buy with a $7.00 target. These three average about $6.17, rounded to a clean $6.00 central target. The low-to-high range of $5.00 to $7.00 is unusually wide for a stock of this size and reflects genuine disagreement.
Stifel's upgrade cited "more visibly positive" revenue growth and improving adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), while more cautious analysts point to mixed product trends and execution risk. The average analyst price target should be read as a research reference point, not a guarantee.
The stock last traded near $4.03, with a market capitalization of roughly $262 million and a 52-week range of about $1.17 to $5.25. Reaching $6.00 therefore implies a move of approximately 49%, which is a substantial rally even for a volatile small-cap. The company is not yet profitable on a trailing basis, so valuation rests heavily on revenue growth and the pace of margin improvement rather than conventional P/E (price-to-earnings) metrics.
The path toward the target would likely require Treace to sustain improving revenue trends, demonstrate that its expansion beyond the core Lapiplasty franchise is gaining traction, and show that new products such as SpeedMTP, MTA3D, ALIGN3D, and HyperPlate XM are contributing meaningful growth. Management has guided to full-year 2026 revenue of roughly $200 million to $212 million.
The stock's 52-week high near $5.25 is the most relevant near-term resistance level and an important psychological hurdle. The recent trading range has seen support around the low-$3 area, with the stock recovering sharply from a 52-week low near $1.17. A sustained move above the mid-$5 zone would represent a breakout above the prior yearly high, while the $6.00 target sits well above that prior peak and would require the stock to trade at levels not seen in more than a year.
Analyst price targets typically reflect a roughly 12-month horizon, though individual firms may vary and targets are revised frequently around earnings. Investors should watch quarterly revenue and gross margin trends, updates to full-year guidance, adoption of new products, any additional analyst revisions, and broader conditions in the medical technology sector. Any change in the pace of the revenue recovery is likely to move the stock more than any single forecast.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For investors following Treace Medical Concepts, pairing fundamental research with systematic signal tracking can provide a more complete view of evolving market sentiment. Explore the AI Daily Buy/Sell Signals to see how machine-driven analysis can complement your own research process.
The $6.00 central target is the rounded average of three verified analyst price targets spanning $5.00 to $7.00, and it sits about 49% above the latest price near $4.03. The strongest supports are a recent earnings beat, a high-profile analyst upgrade, and a broadening product lineup, while the principal obstacles are uneven revenue, margin pressure from product mix, and persistent losses. The wide analyst range underscores how much depends on execution over the coming quarters. Whether Treace Medical Concepts approaches $6.00 will most likely hinge on sustained revenue acceleration and evidence that new products are converting into durable, profitable growth, with no outcome guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TMCI has been loosely correlated with UTMD. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if TMCI jumps, then UTMD could also see price increases.
| Ticker / NAME | Correlation To TMCI | 1D Price Change % | ||
|---|---|---|---|---|
| TMCI | 100% | +2.09% | ||
| UTMD - TMCI | 48% Loosely correlated | -0.01% | ||
| GMED - TMCI | 45% Loosely correlated | -1.49% | ||
| CRL - TMCI | 39% Loosely correlated | -2.13% | ||
| AZTA - TMCI | 39% Loosely correlated | -1.15% | ||
| MTD - TMCI | 39% Loosely correlated | -0.62% | ||
More | ||||
| Ticker / NAME | Correlation To TMCI | 1D Price Change % |
|---|---|---|
| TMCI | 100% | +2.09% |
| Health Services category (239 stocks) | 1% Poorly correlated | -1.13% |
| Medical/Nursing Services category (138 stocks) | 0% Poorly correlated | -1.46% |